Because DED and corneal diseases can be aggravated by inflammation and oxidative stress [19,20,34], we speculate that the addition of GLP-1 agonists can reduce the incidence of these external eye diseases due to their anti-inflammatory and antioxidant effects [22]. Here, GCG is linked to corneal disorder.